Catálogo de publicaciones - revistas
Muscle and Nerve
Resumen/Descripción – provisto por la editorial
No disponible.
Palabras clave – provistas por la editorial
No disponibles.
Disponibilidad
| Institución detectada | Período | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | desde ene. 1978 / hasta dic. 2023 | Wiley Online Library |
Información
Tipo de recurso:
revistas
ISSN impreso
0148-639X
ISSN electrónico
1097-4598
País de edición
Estados Unidos
Cobertura temática
Tabla de contenidos
doi: 10.1002/mus.24659
Quality of life in amyotrophic lateral sclerosis patients and caregivers: Impact of assistive communication from early stages
Ana Londral; Anabela Pinto; Susana Pinto; Luis Azevedo; Mamede De Carvalho
Palabras clave: Physiology (medical); Cellular and Molecular Neuroscience; Neurology (clinical); Physiology.
Pp. 933-941
doi: 10.1002/mus.25430
Revised upper limb module for spinal muscular atrophy: Development of a new module
Elena S. Mazzone; Anna Mayhew; Jacqueline Montes; Danielle Ramsey; Lavinia Fanelli; Sally Dunaway Young; Rachel Salazar; Roberto De Sanctis; Amy Pasternak; Allan Glanzman; Giorgia Coratti; Matthew Civitello; Nicola Forcina; Richard Gee; Tina Duong; Marika Pane; Mariacristina Scoto; Maria Carmela Pera; Sonia Messina; Gihan Tennekoon; John W. Day; Basil T. Darras; Darryl C. Vivo; Richard Finkel; Francesco Muntoni; Eugenio Mercuri
Palabras clave: Physiology (medical); Cellular and Molecular Neuroscience; Neurology (clinical); Physiology.
Pp. 869-874
doi: 10.1002/mus.26408
Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis
Gary L. Pattee; Emily K. Plowman
; Kendrea L. (Focht) Garand; John Costello; Benjamin Rix Brooks; James D. Berry; Richard A. Smith; Nazem Atassi; Jennifer L. Chapin; Yana Yunusova; Courtney E. McIlduff; Eufrosina Young; Eric A. Macklin; Eduardo R. Locatelli; Vincenzo Silani; Daragh Heitzman; James Wymer; Stephen A. Goutman; Deborah F. Gelinas; Bridget Perry; Paige Nalipinski; Kaila Stipancic; Meghan O'Brien; Stacey L. Sullivan; Erik P. Pioro; Gisella Gargiulo; Jordan R. Green;
Palabras clave: Physiology (medical); Cellular and Molecular Neuroscience; Neurology (clinical); Physiology.
Pp. 531-536
doi: 10.1002/mus.27656
Safety and outcomes of eculizumab for acetylcholine receptor‐positive generalized myasthenia gravis in clinical practice
Joome Suh; Virginia Clarke; Anthony A. Amato; Amanda C. Guidon
<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction/Aims</jats:title><jats:p>Safety and outcomes data on eculizumab for generalized myasthenia gravis (gMG) in clinical practice remain limited. Outcomes and concomitant medication use may differ in practice compared with clinical trials. We analyzed the clinical and safety outcomes of patients who received eculizumab at our institutions.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients with acetylcholine receptor antibody positive (AChR+) gMG, who received ≥1 dose of eculizumab and had ≥1 follow‐up before December 10, 2021, were identified. Data were abstracted by chart review. Outcomes included MG Foundation of America Post Intervention Status (MGFA‐PIS), Clinical Classification (MGFA‐CC), MG‐Activities of Daily Living (MG‐ADL), concurrent immunomodulatory therapy use, and adverse events.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Twelve patients were included. Mean age at eculizumab initiation was 57.4 y (range, 21–77). Eight had refractory MG. Four had history of thymoma and thymectomy. A mean of 3.2 (range, 2–5) immunomodulatory therapies were previously tried. Mean follow‐up duration was 18 mo (range, 2–21.6). Clinical improvement occurred rapidly; MGFA‐PIS was improved in 80%, and MGFA‐CC improved in 83% at 1 mo. Mean MG‐ADL decreased from 8.7 to 2.8 at 1 mo, and remained .5 over 1.5 y. Mean daily prednisone dose decreased from 22.5 mg to 7.2 mg at 1.5 y. Five of 7 patients discontinued maintenance IVIG or PLEX. No patients had meningococcal infections and adverse events were mild.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>Clinical improvement occurred in most patients after eculizumab initiation, beginning as quickly as 1 mo. Steroids were tapered and maintenance IVIG and PLEX were discontinued in most. Eculizumab had a favorable safety profile even when combined with other immunosuppressants.</jats:p></jats:sec>
Pp. 348-353
doi: 10.1002/mus.27664
Using machine learning algorithms to enhance the diagnostic performance of electrical impedance myography
Sarbesh R. Pandeya; Janice A. Nagy; Daniela Riveros; Carson Semple; Rebecca S. Taylor; Alice Hu; Benjamin Sanchez; Seward B. Rutkove
Palabras clave: Physiology (medical); Cellular and Molecular Neuroscience; Neurology (clinical); Physiology.
Pp. 354-361
doi: 10.1002/mus.27712
Pain perception during electrodiagnostic studies and the impact of learners
Freddy Paiz; Gyl Midroni; Charles D. Kassardjian
Palabras clave: Physiology (medical); Cellular and Molecular Neuroscience; Neurology (clinical); Physiology.
Pp. 621-624
doi: 10.1002/mus.27706
Traumatic injury to peripheral nerves
Lawrence R. Robinson
<jats:title>Abstract</jats:title><jats:p>This article reviews the epidemiology, classification, localization, prognosis, and mechanisms of recovery of traumatic peripheral nerve injuries (PNIs). Electrodiagnostic (EDx) assessments are critical components of treating patients with PNIs. In particular, motor and sensory nerve conduction studies, needle electromyography, and other electrophysiological methods are useful for localizing peripheral nerve injuries, detecting and quantifying the degree of axon loss, and contributing toward treatment decisions as well as prognostication. It is critical that EDx medical consultants are aware of the timing of these changes as well as limitations in interpretations. Mechanisms of recovery may include recovery from conduction block, muscle fiber hypertrophy, distal axonal sprouting, and axon regrowth from the site of injury. Motor recovery generally reaches a plateau at 18 to 24 months postinjury. When patients have complete or severe nerve injuries they should be referred to surgical colleagues early after injury, as outcomes are best when nerve transfers are performed within the first 3 to 6 months after onset.</jats:p>
Pp. 661-670
doi: 10.1002/mus.27732
Imaging of neuralgic amyotrophy in the acute phase
Paolo Ripellino; Zsuzsanna Arányi; Nens van Alfen; Elisa Ventura; Anne‐Kathrin Peyer; Alessandro Cianfoni; Claudio Gobbi; Emily Pedrick; Darryl Brett Sneag
Palabras clave: Physiology (medical); Cellular and Molecular Neuroscience; Neurology (clinical); Physiology.
Pp. 709-714
doi: 10.1002/mus.27758
Necrotizing myopathy with elevated anti‐HMGCR antibodies following exposure to the supplement Bacopa
Amanda M. Yaworski; Michael Blyumin; Tiffany Chang; Andrew L. Mammen; Maxwell Greene
Pp. No disponible
doi: 10.1002/mus.27777
Electrosonomyography: Avoiding the scalpel in traumatic nerve injury?
Neil G. Simon; Andrew Hannaford
Palabras clave: Physiology (medical); Cellular and Molecular Neuroscience; Neurology (clinical); Physiology.
Pp. 189-190